Showing results (41-50 of 50) with videos related to
Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 50 results.
Journal of Medicinal Chemistry|May 27, 1994
Nitrobenzyl phosphorodiamidates as potential hypoxia-selective alkylating agentsR T Mulcahy, J J Gipp, J P Schmidt, et al.The Journal of Pediatrics|May 1, 1989
Deuterium oxide as a tracer for measurement of compliance in pediatric clinical drug trialsL E Rodewald, L A Maiman, H R Foye, et al.Cancer Research|June 1, 1986
Selective protection against cis-diamminedichloroplatinum(II)-induced toxicity in kidney, gut, and bone marrow by diethyldithiocarbamateD L Bodenner, P C Dedon, P C Keng, et al.Cancer Treatment Reports|November 1, 1982
Cisplatin urinary pharmacokinetics and nephrotoxicity: a common circadian mechanismF Levi, W J Hrushesky, R F Borch, et al.Journal of Medicinal Chemistry|January 5, 2001
Antitumor activity and toxicity of novel nitroheterocyclic phosphoramidatesR F Borch, J Liu, C Joswig, et al.Journal of the National Cancer Institute|November 16, 1988
Phase I clinical and pharmacokinetic study of diethyldithiocarbamate as a chemoprotector from toxic effects of cisplatinR Qazi, A Y Chang, R F Borch, et al.Journal of Medicinal Chemistry|June 8, 2000
Synthesis and evaluation of nitroheterocyclic phosphoramidates as hypoxia-selective alkylating agentsR F Borch, J Liu, J P Schmidt, et al.Cancer Treatment Reports|November 1, 1982
Influence of diuretics on urinary general base catalytic activity and cyclophosphamide-induced bladder toxicityN E Sladek, P C Smith, P M Bratt, et al.Cancer Chemotherapy and Pharmacology|January 1, 1989
High-dose cisplatin with diethyldithiocarbamate (DDTC) rescue therapy: preliminary pharmacologic observationsM W DeGregorio, D R Gandara, W M Holleran, et al.Cancer Research|July 4, 1998
Tumor efficacy and bone marrow-sparing properties of TER286, a cytotoxin activated by glutathione S-transferaseA S Morgan, P E Sanderson, R F Borch, et al.Pageof 5